Pharmacy News Article

Jul 29, 2010 (Datamonitor via COMTEX) Abbott, a health care company, has received FDA approval for two new dosage strengths of Simcor, a cholesterol medication.

The new Simcor dosage strengths combine 40mg of simvastatin, the most commonly prescribed dose of simvastatin, with either 500mg or 1,000mg of niacin extended-release. Simcor is the first treatment to combine Abbott's proprietary niacin extended-release and simvastatin, the most commonly used statin, the company said.

According to the company, Simcor was approved by the FDA in February 2008 in the following strengths: 500mg/20mg, 750mg/20mg and 1,000mg/20mg. The original FDA approval was supported by results from the Seacoast trial, which demonstrated efficacy and safety of Simcor up to doses of 2,000mg niacin extended-release/40mg simvastatin daily in patients with mixed dyslipidemia and type II hyperlipidemia. The Simcor 40mg strengths will be available in early August 2010.

Eugene Sun, vice president of global pharmaceutical development for Abbott, said: "Approval of the new Simcor dosage strengths means that physicians and patients now have more options to treat complex lipid disease."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon